ClinicalTrials.gg
WithdrawnNCT00577109Updated Jul 31, 2018

A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Previously Untreated Metastatic Colorectal Cancer.

A Phase 2 interventional study of bevacizumab [Avastin] and Irinotecan in Colorectal Cancer, sponsored by Hoffmann-La Roche. Withdrawn at 3 sites in Brazil. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-07-31.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

Why this study was withdrawn
Study was cancelled before patient enrollment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 187 studies testing cetuximab in Colorectal Neoplasms — 35 open to participants now, 43 under way, 7 of them phase 3. Cetuximab · Colorectal Neoplasms.

Enrollment
180th of 185
0 · median 60
Started
2007
with 18 others
Phase 2
107 of 187
20 open now
Registered
56th of 187
by date
Lead sponsor
3 of 187
Hoffmann-La Roche

Among the 187 studies testing cetuximab in Colorectal Neoplasms, this one is the 180th largest by enrollment of the 185 interventional ones that give a count, is one of 19 that started in 2007, is one of 107 in phase 2, and was the 56th registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

35 of the 187 studies testing cetuximab in Colorectal Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

30 more — sign in →

By country, each count listing its studies:

All 35 open studies →

About cetuximab

Cetuximab: first FDA approval 2004 (ERBITUX), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,181 Colorectal Neoplasms studies recruiting now, 764 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 187 studies testing cetuximab in Colorectal Neoplasms, or all of them as a file.
02

Study summary

This single arm study will assess the efficacy and safety of a combination of modified FOLFIRI (irinotecan, 5-FU and leucovirin), Avastin and cetuximab in patients with previously untreated metastatic colorectal cancer. Patients will receive modified FOLFIRI (irinotecan 180mg/m2 iv, leucovirin 200mg/m2 iv, and 5-FU 400mg/m2 iv) on day 1 of each 2 week cycle, in combination with Avastin (5mg/kg iv on day 1 of each cycle) and cetuximab (loading dose of 400mg/m2 followed by 250mg/m2 on day 3 of each cycle). The anticipated time on study treatment is until disease progression or unacceptable toxicity, and the target sample size is \<100 individuals.

03

Conditions studied

  • Colorectal Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • adult patients, >=18 years of age;
  • colorectal cancer;
  • advanced or recurrent disease;
  • >=1 ;
  • >=6 months since prior therapy, and >=4 weeks since prior radiotherapy.

Exclusion criteria

Exclusion Criteria:

  • previous treatment for colorectal cancer;
  • significant history of cardiac disease in past 6 months;
  • other invasive within past 5 years, except for nonmelanoma skin cancer, and successfully treated cervical or prostate cancer.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    1

    Drug: bevacizumab [Avastin] · Drug: Irinotecan · Drug: Leucovorin · Drug: 5 FU · Drug: Cetuximab

Interventions

  • 5mg/kg iv on day 1 of each 2 week cycle

  • 180mg/m2 iv on day 1 of each 2 week cycle

  • 200mg/m2 iv on day 1 of each 2 week cycle

  • Drug5 FU

    400mg/m2 iv on day 1 of each 2 week cycle

  • Loading dose of 400mg/m2 iv followed by 250mg/m2 iv on day 3 of each 2 week cycle

06

What researchers measure

Primary outcomes

  1. Progression-free survival

    Time frame: 12 months

Secondary outcomes

  1. Objective response rate, rate of resection of hepatic metastases, overall survival.

    Time frame: Event driven

  2. AEs, laboratory parameters.

    Time frame: Throughout study

07

Study locations

3 sites
  • Salvador, Brazil
  • Sao Paulo, Brazil
  • Sorocaba, Brazil
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2007; primary completion for Jun 2012, 54 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 18, 2007
First posted
Dec 19, 2007
StartEst.
Dec 2007
Primary completionEst.
Jun 2012
CompletionEst.
Jun 2012
Last update
Jul 31, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 31, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00577109
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Dec 19, 2007
Start date
Dec 2007 (estimated)
Primary completion
Jun 2012 (estimated)
Completion
Jun 2012 (estimated)
Last update
Jul 31, 2018

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Aug 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cetuximab

Start the discussion